S. Doerfel

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).

C. Bokemeyer, A. Hinke, A. Stein, 2020 .

Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study

H. Safran, B. Karaszewska, S. Bauer, 2017, International Journal of Hematology.

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

F. Bosch, H. Döhner, M. Hallek, 2016 .

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

C. Bokemeyer, A. Hinke, A. Stein, 2018 .

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial

W. Brugger, C. Ziske, R. Sauter, 2017, British journal of haematology.

Nab-paclitaxel/gemcitabine first-line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin levels: Data from the German QoliXane Pancreatic Cancer Registry.

M. Stauch, R. Hofheinz, J. Roemmler-Zehrer, 2016 .